REVIEW OF AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CLINICAL GUIDELINES FOR THE PREVENTION AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS
https://doi.org/10.14412/1995-4484-2018-144-151
Abstract
Glucocorticoids (GCs) play an important role in treating many inflammatory diseases due to their anti-inflammatory and immunomodulatory activities and are used in many fields of medicine. Despite their clinical benefits of GCs used to treat patients with chronic inflammatory diseases, prolonged administration of these medications, especially oral ones, frequently causes serious complications, such as bone loss and fractures. The present paper reviews the latest American College of Rheumatology clinical guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis, which were published in 2017. It provides comments, by taking into account the Russian guidelines on the diagnosis, prevention, and treatment of glucocorticoid-induced osteoporosis.
About the Author
N. V. Toroptsova
V.A.Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Natalia Toroptsova.
34A, Kashirskoe Shosse, Moscow 115522
References
1. Hench PS, Kendall EC, Slocumb CH, Polley HF. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocortical hormone in arthritis: preliminary report. Ann Rheum Dis. 1949 Jun;8 (2):97-104. doi: 10.1136/ard.8.2.97
2. Pope JE, Hong P, Koehler BE. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologist. J Rheumatol. 2002;29:255-60.
3. Thiele K, Buttgereit F, Huscher D, Zink A. Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. Arthritis Rheum. 2005;53:740-7. doi: 10.1002/art.21467
4. Sokka T, Kautiainen N, Toloza S, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis. 2007;66:1491-6. doi: 10.1136/ard.2006.069252
5. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004 Jun;19(6):893-9. doi: 10.1359/jbmr.040134
6. Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in UK over the past 20 years. Rheumatology (Oxford). 2011;50:1982-90. doi: 10.1093/rheumatology/ker017
7. Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids in the United Kingdom. QJM. 2000;93(2):105-11. doi: 10.1093/qjmed/93.2.105
8. Baranova IA, Ershova OB, Avdeeva OS, et al. The first results of a study on the state of medical care with glucocorticoid osteoporosis and the risk of its development (GLUCOST). Materials of the V Russian Congress on Osteoporosis and Other Metabolic Diseases of the Skeleton. Osteoporoz i Osteopatiya. 2013;Suppl:120-1 (In Russ.).
9. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002 Oct;13(10):777-87. doi: 10.1007/s001980200108
10. Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000 Jun;15(6):993-1000. doi: 10.1359/jbmr.2000.15.6.993
11. Curtis J, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55:420-6. doi: 10.1002/art.21984
12. Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone. 2006;39:253-9. doi: 10.1016/j.bone.2006.02.005
13. Van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000 Dec;39(12):1383-9. doi: 10.1093/rheumatology/39.12.1383
14. Laan RF, van Riel PL, van de Putte LB, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis: a randomized, controlled study. Ann Intern Med. 1993;119:963-8. doi: 10.7326/0003-4819-119-10-199311150-00001
15. Hansen KE, Kleker B, Safdar N, Bartels CM. A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children. Semin Arthritis Rheum. 2014;44:47-54. doi: 10.1016/j.semarthrit.2014.02.002
16. LeBlanc CM, Ma J, Taljaard M, et al. Incident vertebral fractures and risk factors in the first three years following glucocorticoid initiation among pediatric patients with rheumatic disorders. J Bone Miner Res. 2015;30:1667-75. doi: 10.1002/jbmr.2511
17. Hall GM, Spector TD, Griffin AJ, et al. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum. 1993;36:1510-6. doi: 10.1002/art.1780361105
18. Sugiyama T, Suzuki S, Yoshida T, et al. Incidence of symptomatic vertebral fractures in women of childbearing age newly treated with high-dose glucocorticoid. Gend Med. 2010;7:218-29. doi: 10.1016/j.genm.2010.06.004
19. Li EK, Tam LS, Griffith JF, et al. High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus. J Rheumatol. 2009;36:1646-52. doi: 10.3899/jrheum.081337
20. Borba VZ, Matos PG, da Silva Viana PR, et al. High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients. Lupus. 2005;14:529-33. doi: 10.1191/0961203305lu2154oa
21. Baranova IA, Ershova OB, Anaev EKh, et al. Analysis of the state-of-the-art of consulting medical care to patients with glucocorticoid-induced osteoporosis or its risk according to the data of a questionnaire survey (GLUCOST study). Terapevticheskii Arkhiv. 2015;(5):58-64 (In Russ.). doi: 10.17116/terarkh201587558-64
22. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2017;69(8):1521-37. doi: 10.1002/art.40137
23. Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22:809-16. doi: 10.1007/s00198-010-1524-7
24. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62:1515-26. doi: 10.1002/acr.20295
25. Dawson-Hughes B, Tosteson AN, Melton LJ III, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19:449-58. doi: 10.1007/s00198-008-0559-5
26. Kanis JA, McCloskey EV, Johansson H, et al. Development and use of FRAX in osteoporosis. Osteoporos Int. 2010;21 Suppl 2(S2):S407-13. doi: 10.1007/s00198-010-1253-y
27. Baranova IA, Belaya ZhE, Gasser RV, et al. Osteoporoz: Rukovodstvo dlya vrachei [Osteoporosis: A guide for doctors]. Moscow; 2016. 464 p. (In Russ.).
28. Торопцова НВ, Баранова ИА. Глюкокортикоидный остеопороз: особенности терапии. Современная ревматология. 2013;7(4):33-7 [Toroptsova NV, Baranova IA. Glucocorticoid osteoporosis; osteoporotic fracture; bisphosphonates. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2013;7(4):33-7 (In Russ.)]. doi: 10.14412/1996-7012-2013-2436
29. Holick MF. Optimal vitamin D status for the prevention and treatment of osteoporosis. Drugs Aging. 2007;24:1017-29. doi: 10.2165/00002512-200724120-00005
30. Belaya ZhE, Belova KYu, Bordakova EV, et al. Profilaktika, diagnostika i lechenie defitsita vitamina D i kal'tsiya sredi vzroslogo naseleniya i u patsientov s osteoporozom. Rekomendatsii Rossiiskoi assotsiatsii po osteoporozu [Prophylaxis, diagnosis and treatment of vitamin D and calcium deficiency in the adult population and in patients with osteoporosis. Recommendations of the Russian Association for Osteoporosis]. Moscow: GEOTAR-Media; 2016. 96 p. (In Russ.).
31. De Nijs RN, Jacobs JW, Algra A, et al. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int. 2004;15(8):589-602. doi: 10.1007/s00198-004-1614-5
32. Hoes JN, Jacobs JW, Hulsmans HM, et al. High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial. Clin Exp Rheumatol. 2010;28(3):354-9.
Review
For citations:
Toroptsova N.V. REVIEW OF AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CLINICAL GUIDELINES FOR THE PREVENTION AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS. Rheumatology Science and Practice. 2018;56(2):144-151. (In Russ.) https://doi.org/10.14412/1995-4484-2018-144-151
Views:
1252
Email this article 